-transparent.png){kind=logo}
Lisuride was investigated for therapeutic effects in 19 patients with advanced Parkinson disease, no longer satisfactorily responding to routine L-Dopa therapy. The patients were treated with oral Lisuride (0.6-2.5 mg/die) and L-Dopa. The follow-up was at least 6 months. We noted a significant improvement on the Webster Rating Scale at 1st, 3rd and 6th months. Disability and on-off phenomen were reduced. Side effects were few. Lisuride is a valuable tool in this type of patient.
Related Publications
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
November 1981,
Neurology,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
January 1985,
Medicina,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
January 1983,
Annals of neurology,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
August 1981,
Neurology,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
April 1987,
Wiener medizinische Wochenschrift (1946),
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
May 1998,
Internal medicine (Tokyo, Japan),
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
June 1982,
Neurology,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
September 1985,
The American journal of the medical sciences,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
January 1984,
Advances in neurology,
F Degl'Innocenti, and
A Ginanneschi, and
S Magnolfi, and
L Catarzi, and
P Marini
January 1992,
Acta histochemica. Supplementband,
